

Attorney Docket No. Le A 33 861

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lerchen, et al.

Group No.:

Serial No.: National Stage Filing of PCT/EP00/08361

Examiner:

Filing Date: FEB 26 2002

For: Integrin-mediated Drug Targeting

BOX PCT  
ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 48,972

Telephone: (203) 812-6450

Date: FEB 26 2002

  
Susan M. Pellegrino  
Attorney for Applicant(s)  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516

Form PTO-1449  
(Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Serial No.

Group Art Unit

Filing Date

Atty. Docket No.

FEB 26 2002

Le A 33 861

Applicant(s)

Lerchen, et al.

# INFORMATION DISCLOSURE CITATION

## FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.							DATE	COUNTRY	PRIMARY	S U B	TRANSLATION	
								DD/MM/YY		CLASS	CLASS	YES	NO
<b>F<sub>1</sub></b>	9	3	2	0	2	2	9	14/10/93	WO				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

- R<sub>1</sub>** Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S., Gladson, C. L., "Vitronectin, a Glioma-derived Extracellular Matrix Protein, Protects Tumor Cells from Apoptotic Death", Clinical Cancer Research, 5: 1587-1594 (June 1999)
- R<sub>2</sub>** Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., Dalton, W. S., "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrin and Resistance to Apoptosis in Human Myeloma Cell Lines", Blood, 93(5): 1658-1667 (March 1999)
- R<sub>3</sub>** Varner, J. A., Cheresh, D. A., "Integrins and Cancer", Current Opinion in Cell Biology, 8: 724-730 (1996)
- R<sub>4</sub>** Bitan, G., Scheibler, L., Greenberg, Z., Rosenblat, M., Chorev, M., "Mapping the Integrin  $\alpha v \beta 3$ -Ligand Interface by Photoaffinity Cross-Linking", Biochemistry, 38: 3414-3420 (1999)
- R<sub>5</sub>** Fields, G. B., "Integrins: cell adhesion molecules in cancer", Exp. Opin. Ther. Patents, 8(6): 633-644 (1998)
- R<sub>6</sub>** Kerr, J. S., "Novel Small Molecule  $\alpha v$  Integrin Antagonists: Comparative Anti-Cancer Efficacy with Known Angiogenesis Inhibitors", Anticancer Research, 19(2A): 959-968 (1999)
- R<sub>7</sub>** Carron, C. P., "A Peptidomimetic Antagonist of the Integrin  $\alpha v \beta 3$  Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy", Cancer Res., 58: 1930-1935 (May 1998)
- R<sub>8</sub>** Nickols, A., "Antiangiogenic and Anticancer Activities of Antagonists of Integrin  $\alpha v \beta 3$ ", Proc. Annu. Meet. AACR., 38(1): 206 (March 1997), Abstract No. 1389
- R<sub>9</sub>** Macdonald, T. J., "Migration of Human Brain Tumor Cells and Human Brain Endothelial Cells on Tenscin Requires the Integrin  $\alpha v \beta 3$ ; a Unifying Model for Brain Tumor Invasion and Angiogenesis", Proc. Annu. Meet., AACR., 39: 497 (March 1998), Abstract No. 3382
- R<sub>10</sub>** Brooks, P. C., "Requirement of Vascular Integrin  $\alpha v \beta 3$  for Angiogenesis", Science, 264: 569-571 (April 1994)
- R<sub>11</sub>** Brooks, P. C., "Integrin  $\alpha v \beta 3$  Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels", Cell, 79(7): 1157-1164 (Dec. 1994)
- R<sub>12</sub>** Varner, J. A., "Tumor Angiogenesis and The Role of Vascular Cell Integrin  $\alpha v \beta 3$ ", Important Advances in Oncology, pp. 69-87 (1996)
- R<sub>13</sub>** Varner, J. A., "Review: The Integrin  $\alpha v \beta 3$ : Angiogenesis and Apoptosis", Cell Adhesion and Communication, 3(4): 367-374 (1995)

EXAMINER

DATE CONSIDERED

26 FEB 2002

Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Serial No.

Group Art Unit

Filing Date

Atty. Docket No.

FEB 26 2002

Le A 33 861

Applicant(s)

Lerchen, et al.

## INFORMATION DISCLOSURE CITATION

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

- R<sub>14</sub>** Gasparini, G., "The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasma", *Drugs*, 58(1): 17-38 (July 1999)
- R<sub>15</sub>** Mueller, B. M., "Pre-clinical Therapy of Human Melanoma with Morpholino-doxorubicin Conjugated to a Monoclonal Antibody Directed Against an Integrin on Melanoma Cells", *Antibody, Immunoconjugates, Radiopharm.*, 4(2): 99-106 (1991)
- R<sub>16</sub>** Sheu Joen, R., "Triflavin, an arg-gly-asp-containing peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells", *Proc. Soc. Exp. Biol. Med.*, 213(1): 71-79 (1996)

EXAMINER

DATE CONSIDERED